These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36372934)

  • 21. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation.
    Martial LC; Hoogtanders KEJ; Schreuder MF; Cornelissen EA; van der Heijden J; Joore MA; Van Maarseveen EM; Burger DM; Croes S; Brüggemann RJM; Aarnoutse RE
    Ther Drug Monit; 2017 Aug; 39(4):412-421. PubMed ID: 28700522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application.
    Kloosterboer SM; de Winter BCM; Bahmany S; Al-Hassany L; Dekker A; Dieleman GC; van Gelder T; Dierckx B; Koch BCP
    Ther Drug Monit; 2018 Jun; 40(3):344-350. PubMed ID: 29505492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Validation of a Dried Blood Spot Assay for 8 Antihypertensive Drugs and 4 Active Metabolites.
    Peeters LEJ; Feyz L; Hameli E; Zwart T; Bahmany S; Daemen J; van Gelder T; Versmissen J; Koch BCP
    Ther Drug Monit; 2020 Jun; 42(3):460-467. PubMed ID: 31593031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
    Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validated HPLC method for ceftriaxone from dried blood spots for pharmacokinetic studies and therapeutic drug monitoring in neonatal population.
    Chaudhari BB; Devadiga BH; Matcha S; Lewis LE; Mallayasamy S; Moorkoth S
    Bioanalysis; 2023 Apr; 15(8):449-463. PubMed ID: 37216211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring.
    Koller D; Vaitsekhovich V; Mba C; Steegmann JL; Zubiaur P; Abad-Santos F; Wojnicz A
    Talanta; 2020 Feb; 208():120450. PubMed ID: 31816725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS.
    Damaraju VL; Weber D; Kuzma M; Cass CE; Sawyer MB
    J Biol Chem; 2016 Sep; 291(36):18809-17. PubMed ID: 27432881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
    Breccia M; Chiodi F; Nardozza AP; Valsecchi D; Perrone V; Sangiorgi D; Giacomini E; Rendace MC; Coco P; Premoli E; Degli Esposti L
    Adv Ther; 2023 Mar; 40(3):961-974. PubMed ID: 36562943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
    O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ
    Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
    Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
    Casavecchia G; Spinosa G; De Gennaro L; Zicchino S; Gravina M; Magnesa M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Apr; 77(2):130-135. PubMed ID: 33685352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A rapid and sensitive ultra-performance liquid chromatography tandem mass spectrometry method for determination of anlotinib in plasma and dried blood spots: Method development, validation, and clinical application.
    Zhang J; Wang W; Du J; Li C; Wang S; Han Y; Wang H; Zong H; Cheng Z; Tian X
    Rapid Commun Mass Spectrom; 2022 Nov; 36(21):e9372. PubMed ID: 35918299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
    Antunes MV; Raymundo S; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra MZ; Fogliatto L; Linden R
    Bioanalysis; 2015; 7(16):2105-17. PubMed ID: 26327189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ever-advancing chronic myeloid leukemia treatment.
    Kimura S; Ando T; Kojima K
    Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.
    Parsons TL; Marzinke MA; Hoang T; Bliven-Sizemore E; Weiner M; Mac Kenzie WR; Dorman SE; Dooley KE
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6747-57. PubMed ID: 25182637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.